Chimeric Antigen Receptor (CAR) T cell therapy is a revolutionary approach in the field of cancer immunotherapy.
Chimeric Antigen Receptor (CAR) T Cell Therapy
Moving Forward in Diagnosing Ulcerative Colitis
Inflammatory bowel disease (IBD), which affects millions of people worldwide, is made up of various conditions that cause chronic inflammation of the gastrointestinal (GI) tract. The two main conditions are ulcerative colitis and Crohn’s disease. Crohn’s disease can affect any
Immune Checkpoints
ProSci offers reagents that can be used to study the actions of multiple immune checkpoint proteins such as CTLA-4, PD-1, & its ligands PD-L1 & PD-L2.
Viral Infectious Diseases
To support research & studies into infectious diseases, ProSci has reagents for the study of many viral disease agents inc. Covid, HIV, & Influenza.
How AllCells’ Expanded Donor Collection Facilities Help You to Recruit the Right Donors and Scale Your Cell and Gene Therapy Development
AllCells’ has thousands of well-characterised, highly engaged recallable donors, with specific attributes, at collection sites across the US & Europe.
Overcoming the Donor Selection Challenges to Drive Success in Cell and Gene Therapy Development and Commercialisation
AllCells’ Pre-Characterised Donor Selection Program expedites screening, selecting & collecting from donors for downstream clinical manufacturing.
Reframing the Inherent Donor Supply Chain Ecosystem to Support the Imminent CGT Manufacturing Boom: Recap of the Allogeneic Cell Therapies Summit 2023
Key takeaways from AllCells’ VP of Donor Operations presentation on reframing the donor supply chain ecosystem to support the CGT manufacturing boom.
The World’s Largest Apheresis Network Serves as a Catalyst to Advance Cell and Gene Therapies
AllCells and Discovery continue to expand their solutions alongside the CGT industry to help researchers overcome roadblocks.
Therapeutic Targets of the NAD+ Biosynthesis Pathway
CycLex NAMPT Colorimetric Assay Kit detects nicotinamide phosphoribosyltransferase (NAMPT) activity in recombinant NAMPT or endogenous NAMPT immunoprecipitated from cell extract.
Cancer Immunotherapy: An increasing emphasis on CD4+ T cells and MHC Class II Neoantigens
QuickSwitch™ Class II Tetramer Peptide Exchange and Quantitation Kit utilises a patented technique for exchanging up to ten peptides on an MHC Class II Tetramer.